Stuart Poulton sold $3,262 of KPTI
EVP, Chief Development Officer at Karyopharm Therapeutics Inc.. 378 shares at an average of $8.63, traded Feb 17, 2026, filed Feb 19, 2026.
Score components
- +15RoleOfficer
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.4% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-059332, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | SOpen-market sale Common Stock | -378 | $8.63 | $3,262 | 99,429 | Feb 19, 2026 |
Related signals
Other insiders at Karyopharm Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $450 378 shares | -2% | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $38 19 shares | -0% | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $504 53 shares | -0% | |
| 30Weak | Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $5,260 559 shares | -2% | |
| 36Weak | Karyopharm Therapeutics Inc. | Sohanya Roshan Cheng EVP & Chief Commercial Officer | $43k 4,604 shares | -4% | |
| 50Moderate | Karyopharm Therapeutics Inc. | Richard A. Paulson President and CEO | $116k 12,361 shares | -4% | |
| 37Weak | Karyopharm Therapeutics Inc. | Reshma Rangwala EVP & Chief Medical Officer | $48k 5,066 shares | -8% | |
| 36Weak | Karyopharm Therapeutics Inc. | Michael Mano EVP, CLO&Secretary | $33k 3,526 shares | -4% | |
| 37Weak | Karyopharm Therapeutics Inc. | Stuart Poulton EVP, Chief Development Officer | $48k 5,101 shares | -5% | |
| 37Weak | Karyopharm Therapeutics Inc. | Lori Macomber EVP, CFO & Treasurer | $10k 1,626 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.